New imaging agent could sharpen lung cancer detection
NCT ID NCT07007325
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test a new radioactive tracer called [68Ga]Ga-PentixaFor in 15 people with metastatic small cell lung cancer. The goal is to see if this PET-CT scan can find tumors as well as the standard FDG PET-CT scan, both at diagnosis and when the disease gets worse. If it works, it may offer a more precise way to image this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [68Ga]Ga-PentixaFor (a radioactive tracer for PET-CT imaging)
- What this could lead to
- If successful, this could lead to a more accurate imaging method for detecting small cell lung cancer spread, helping doctors choose better treatments.
- What could go wrong
- This is a very early, small pilot study with only 15 participants. The new tracer may not detect tumors as well as the standard scan, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA (SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU d'Angers
Angers, 49100, France
-
Institut de cancérologie de l'ouest
Angers, 49055, France
-
Institut de cancérologie de l'ouest
Saint-Herblain, 44805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.